Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131801) titled 'Correlation Between Gut Microbiota and the Clinical Efficacy of Immune Checkpoint Inhibitors Combined With Anti-angiogenic Targeted Therapy in Renal Cancer: A Prospective, Single-center, Observational Study' on Sept. 7.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Shanghai Changhai Hospital
Condition:
Kidney cancer
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-04-17
Target Sample Size: Clinical benefit/non-benefit observation group for renal cancer:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html...